BR112015003201A2 - composto, composição farmacêutica, uso de um composto e método para tratar ou melhorar o cãncer - Google Patents
composto, composição farmacêutica, uso de um composto e método para tratar ou melhorar o cãncerInfo
- Publication number
- BR112015003201A2 BR112015003201A2 BR112015003201A BR112015003201A BR112015003201A2 BR 112015003201 A2 BR112015003201 A2 BR 112015003201A2 BR 112015003201 A BR112015003201 A BR 112015003201A BR 112015003201 A BR112015003201 A BR 112015003201A BR 112015003201 A2 BR112015003201 A2 BR 112015003201A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treating
- pharmaceutical composition
- ameliorating cancer
- ameliorating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683253P | 2012-08-15 | 2012-08-15 | |
| PCT/EP2013/066458 WO2014026882A1 (en) | 2012-08-15 | 2013-08-06 | Azaheterocycles as bir2 and/or bir3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015003201A2 true BR112015003201A2 (pt) | 2017-07-04 |
Family
ID=48948413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015003201A BR112015003201A2 (pt) | 2012-08-15 | 2013-08-06 | composto, composição farmacêutica, uso de um composto e método para tratar ou melhorar o cãncer |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9422332B2 (pt) |
| EP (1) | EP2885275A1 (pt) |
| JP (1) | JP6203261B2 (pt) |
| KR (1) | KR20150042792A (pt) |
| CN (1) | CN104540806B (pt) |
| AU (1) | AU2013304214A1 (pt) |
| BR (1) | BR112015003201A2 (pt) |
| CA (1) | CA2878106A1 (pt) |
| CL (1) | CL2015000333A1 (pt) |
| CO (1) | CO7180196A2 (pt) |
| CR (1) | CR20150041A (pt) |
| EA (1) | EA201590347A1 (pt) |
| HK (1) | HK1209427A1 (pt) |
| IL (1) | IL237063A0 (pt) |
| MA (1) | MA37896A1 (pt) |
| MX (1) | MX2015001905A (pt) |
| PE (1) | PE20150674A1 (pt) |
| PH (1) | PH12015500185B1 (pt) |
| SG (1) | SG11201500581WA (pt) |
| WO (1) | WO2014026882A1 (pt) |
| ZA (1) | ZA201500342B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| ES2899002T3 (es) * | 2016-03-22 | 2022-03-09 | Inst Nat Sante Rech Med | Nuevos derivados y su uso como inhibidores selectivos de Caspasa-2 |
| US10398702B2 (en) * | 2016-05-09 | 2019-09-03 | Hoffmann-La Roche Inc. | Dimeric compounds |
| CN106265764B (zh) | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101094833A (zh) * | 2004-07-12 | 2007-12-26 | 伊邓药品公司 | 四肽类似物 |
| EA200700225A1 (ru) | 2004-07-12 | 2008-02-28 | Айдан Фармасьютикалз, Инк. | Аналоги тетрапептида |
| US8551955B2 (en) * | 2009-10-28 | 2013-10-08 | Joyant Pharmaceuticals, Inc. | Dimeric Smac mimetics |
-
2013
- 2013-08-06 US US14/419,288 patent/US9422332B2/en not_active Expired - Fee Related
- 2013-08-06 CN CN201380035682.3A patent/CN104540806B/zh not_active Expired - Fee Related
- 2013-08-06 MA MA37896A patent/MA37896A1/fr unknown
- 2013-08-06 CA CA2878106A patent/CA2878106A1/en not_active Abandoned
- 2013-08-06 BR BR112015003201A patent/BR112015003201A2/pt active Search and Examination
- 2013-08-06 KR KR20157003782A patent/KR20150042792A/ko not_active Application Discontinuation
- 2013-08-06 PE PE2015000194A patent/PE20150674A1/es not_active Application Discontinuation
- 2013-08-06 AU AU2013304214A patent/AU2013304214A1/en not_active Abandoned
- 2013-08-06 EA EA201590347A patent/EA201590347A1/ru unknown
- 2013-08-06 SG SG11201500581WA patent/SG11201500581WA/en unknown
- 2013-08-06 WO PCT/EP2013/066458 patent/WO2014026882A1/en active Application Filing
- 2013-08-06 MX MX2015001905A patent/MX2015001905A/es unknown
- 2013-08-06 JP JP2015526932A patent/JP6203261B2/ja not_active Expired - Fee Related
- 2013-08-06 EP EP13745838.6A patent/EP2885275A1/en not_active Withdrawn
-
2015
- 2015-01-16 ZA ZA2015/00342A patent/ZA201500342B/en unknown
- 2015-01-28 CO CO15017272A patent/CO7180196A2/es unknown
- 2015-01-28 PH PH12015500185A patent/PH12015500185B1/en unknown
- 2015-01-29 CR CR20150041A patent/CR20150041A/es unknown
- 2015-02-02 IL IL237063A patent/IL237063A0/en unknown
- 2015-02-11 CL CL2015000333A patent/CL2015000333A1/es unknown
- 2015-10-20 HK HK15110299.0A patent/HK1209427A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015000333A1 (es) | 2015-11-06 |
| KR20150042792A (ko) | 2015-04-21 |
| PH12015500185A1 (en) | 2015-04-20 |
| US20150210739A1 (en) | 2015-07-30 |
| EA201590347A1 (ru) | 2015-05-29 |
| IL237063A0 (en) | 2015-03-31 |
| MX2015001905A (es) | 2015-06-05 |
| JP2015526436A (ja) | 2015-09-10 |
| WO2014026882A1 (en) | 2014-02-20 |
| CR20150041A (es) | 2015-03-13 |
| JP6203261B2 (ja) | 2017-09-27 |
| AU2013304214A1 (en) | 2015-02-12 |
| US9422332B2 (en) | 2016-08-23 |
| CN104540806A (zh) | 2015-04-22 |
| ZA201500342B (en) | 2017-09-27 |
| CN104540806B (zh) | 2017-05-03 |
| EP2885275A1 (en) | 2015-06-24 |
| CA2878106A1 (en) | 2014-02-20 |
| MA37896A1 (fr) | 2016-09-30 |
| SG11201500581WA (en) | 2015-04-29 |
| CO7180196A2 (es) | 2015-02-09 |
| HK1209427A1 (en) | 2016-04-01 |
| PE20150674A1 (es) | 2015-05-06 |
| PH12015500185B1 (en) | 2015-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015004547A2 (pt) | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer | |
| BR112015001830A2 (pt) | composto, uso de um composto, método para o tratamento ou profilaxia de câncer e invenção | |
| BR112014032053A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
| BR112014003681A2 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
| BR112014010179A8 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112015031475A2 (pt) | composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto. | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015004489A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto | |
| BR112013023175A2 (pt) | composto, inibidor, medicamento, agente anticâncer, composição farmacêutica, método para o tratamento de câncer, e, uso de um composto | |
| BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
| BR112014029404A2 (pt) | compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção | |
| BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
| BR112014008126A2 (pt) | composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112012018943A8 (pt) | medicamento e método para o tratamento e/ou prevenção de um câncer | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112015000649A2 (pt) | compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |